Management of Advanced Prostate Cancer in the Precision Oncology Era

被引：13

作者：

Gillette, Claire M. M. ^{[1
]}

Yette, Gabriel A. A. ^{[1
]}

Cramer, Scott D. D. ^{[1
]}

Graham, Laura S. S. ^{[2
]}

机构：

[1] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA

[2] Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA

来源：

CANCERS | 2023年 / 15卷 / 09期

关键词：

metastatic prostate cancer; advanced prostate cancer; biomarkers; genomic selection; chemotherapy; PARP inhibitors; immunotherapy; PSMA; theranostics; radioligand therapy; POSITRON-EMISSION-TOMOGRAPHY; MEMBRANE ANTIGEN-EXPRESSION; PLATINUM-BASED CHEMOTHERAPY; SIPULEUCEL-T; ANALYSIS REVEALS; DOUBLE-BLIND; OPEN-LABEL; CASTRATION; MULTICENTER; DEFICIENCY;

D O I：

10.3390/cancers15092552

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer (PC) is the second leading cause of cancer death in men in the United States. While diversified and improved treatment options for aggressive PC have improved patient outcomes, metastatic castration-resistant prostate cancer (mCRPC) remains incurable and an area of investigative therapeutic interest. This review will cover the seminal clinical data supporting the indication of new precision oncology-based therapeutics and explore their limitations, present utility, and potential in the treatment of PC. Systemic therapies for high-risk and advanced PC have experienced significant development over the past ten years. Biomarker-driven therapies have brought the field closer to the goal of being able to implement precision oncology therapy for every patient. The tumor agnostic approval of pembrolizumab (a PD-1 inhibitor) marked an important advancement in this direction. There are also several PARP inhibitors indicated for patients with DNA damage repair deficiencies. Additionally, theranostic agents for both imaging and treatment have further revolutionized the treatment landscape for PC and represent another advancement in precision medicine. Radiolabeled prostate-specific membrane antigen (PSMA) PET/CT is rapidly becoming a standard of care for diagnosis, and PSMA-targeted radioligand therapies have gained recent FDA approval for metastatic prostate cancer. These advances in precision-based oncology are detailed in this review.

引用

页数：17

共 115 条

[11] FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer [J].

Anscher, Mitchell S. ;

Chang, Elaine ;

Gao, Xin ;

Gong, Yutao ;

Weinstock, Chana ;

Bloomquist, Erik ;

Adeniyi, Oluseyi ;

Charlab, Rosane ;

Zimmerman, Sarah ;

Serlemitsos-Day, Maritsa ;

Ning, Yang Min ;

Mayrosh, Ruth ;

Fuller, Barbara ;

Trentacosti, Ann Marie ;

Gallagher, Pamela ;

Bijwaard, Karen ;

Philip, Reena ;

Ghosh, Soma ;

Fahnbulleh, Frances ;

Diggs, Felicia ;

Arora, Shaily ;

Goldberg, Kirsten B. ;

Tang, Shenghui ;

Amiri-Kordestani, Laleh ;

Pazdur, Richard ;

Ibrahim, Amna ;

Beaver, Julia A. .

ONCOLOGIST, 2021, 26 (02) :139-146

[12] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study [J].

Antonarakis, Emmanuel S. ;

Piulats, Josep M. ;

Gross-Goupil, Marine ;

Goh, Jeffrey ;

Ojamaa, Kristiina ;

Hoimes, Christopher J. ;

Vaishampayan, Ulka ;

Berger, Ranaan ;

Sezer, Ahmet ;

Alanko, Tuomo ;

de Wit, Ronald ;

Li, Chunde ;

Omlin, Aurelius ;

Procopio, Giuseppe ;

Fukasawa, Satoshi ;

Tabata, Ken-ichi ;

Park, Se Hoon ;

Feyerabend, Susan ;

Drake, Charles G. ;

Wu, Haiyan ;

Qiu, Ping ;

Kim, Jeri ;

Poehlein, Christian ;

de Bono, Johann Sebastian .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[13] Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations [J].

Antonarakis, Emmanuel S. ;

Shaukat, Farah ;

Velho, Pedro Isaacsson ;

Kaur, Harsimar ;

Shenderov, Eugene ;

Pardoll, Drew M. ;

Lotan, Tamara L. .

EUROPEAN UROLOGY, 2019, 75 (03) :378-382

[14] Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer [J].

Aparicio, Ana M. ;

Harzstark, Andrea L. ;

Corn, Paul G. ;

Wen, Sijin ;

Araujo, John C. ;

Tu, Shi-Ming ;

Pagliaro, Lance C. ;

Kim, Jeri ;

Millikan, Randall E. ;

Ryan, Charles ;

Tannir, Nizar M. ;

Zurita, Amado J. ;

Mathew, Paul ;

Arap, Wadih ;

Troncoso, Patricia ;

Thall, Peter F. ;

Logothetis, Christopher J. .

CLINICAL CANCER RESEARCH, 2013, 19 (13) :3621-3630

[15]

ASCO, 2021, VISION STUD RES PHAS

[16] Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA [J].

Barata, Pedro ;

Agarwal, Neeraj ;

Nussenzveig, Roberto ;

Gerendash, Benjamin ;

Jaeger, Ellen ;

Hatton, Whitley ;

Ledet, Elisa ;

Lewis, Brian ;

Layton, Jodi ;

Babiker, Hani ;

Bryce, Alan ;

Garje, Rohan ;

Stein, Cy ;

Kiedrowski, Lesli ;

Saylor, Philip ;

Sartor, Oliver .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[17] Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer [J].

Beer, Tomasz M. ;

Kwon, Eugene D. ;

Drake, Charles G. ;

Fizazi, Karim ;

Logothetis, Christopher ;

Gravis, Gwenaelle ;

Ganju, Vinod ;

Polikoff, Jonathan ;

Saad, Fred ;

Humanski, Piotr ;

Piulats, Josep M. ;

Gonzalez Mella, Pablo ;

Ng, Siobhan S. ;

Jaeger, Dirk ;

Parnis, Francis X. ;

Franke, Fabio A. ;

Puente, Javier ;

Carvajal, Roman ;

Sengelov, Lisa ;

McHenry, M. Brent ;

Varma, Arvind ;

van den Eertwegh, Alfonsus J. ;

Gerritsen, Winald .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :40-+

[18]

Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO

[19]

2-S

[20] A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range [J].

Catalona, William J. ;

Partin, Alan W. ;

Sanda, Martin G. ;

Wei, John T. ;

Klee, George G. ;

Bangma, Chris H. ;

Slawin, Kevin M. ;

Marks, Leonard S. ;

Loeb, Stacy ;

Broyles, Dennis L. ;

Shin, Sanghyuk S. ;

Cruz, Amabelle B. ;

Chan, Daniel W. ;

Sokoll, Lori J. ;

Roberts, William L. ;

van Schaik, Ron H. N. ;

Mizrahi, Isaac A. .

JOURNAL OF UROLOGY, 2011, 185 (05) :1650-1655

← 1 2 3 4 5 6 7 8 9 10 →